Haemonetics reported fiscal Q4 revenue of $346 million, up 5% reported and 9% organically excluding CSL. Strength in Plasma and Blood Management Technologies offset continued pressure in Interventional Technologies, resulting in a mixed but slightly positive operating update.
Haemonetics reported fiscal Q4 revenue of $346 million, up 5% reported and 9% organically excluding CSL. Strength in Plasma and Blood Management Technologies offset continued pressure in Interventional Technologies, resulting in a mixed but slightly positive operating update.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
mildly positive
Sentiment Score
0.25
Ticker Sentiment
